Illumina Announces Scale-Up of its Genome Analyzer Sequencing Technology at the Broad Institute
News Apr 17, 2009
Illumina, Inc. has announced that the Broad Institute of MIT and Harvard has acquired 22 additional Genome Analyzers to increase its installed base of the Illumina sequencing platform to 47 units.
"We are excited to build on our strong relationship with Illumina," said Eric S. Lander, Director of the Broad Institute of MIT and Harvard. "We also believe that this partnership will help accelerate the application of genomics to medical practice."
"The Broad Institute's decision to significantly scale their installed base of Genome Analyzers is a tremendous sign of their confidence in our ability to continue improving the performance and economics of the system," said Christian Henry, Senior Vice President and Chief Financial Officer at Illumina.
Over the course of the year Illumina plans to increase the throughput of the Genome Analyzer to as much as 95 gigabases of highly accurate DNA sequence data per single run, or the equivalent of one whole human genome at 30 times coverage.
Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies.
The Genome Analyzer also offers the broadest set of supported applications, including those used to profile and discover novel transcripts, to create a high-resolution genome-wide map of DNA-protein binding sites and to sequence entire human genomes to greater than 30x coverage.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE